Ivan Gergel
InvestorManaging Partner at New Rhein Healthcare Investors, LLC · Board director at Alveus Therapeutics · Board director at Neuraptive
Pennsylvania
Writes $100K – $5M checks · typically $1.5M
About
Ivan Gergel, MD, MBA, has been Managing Partner and Chief Medical Officer at New Rhein since 2017. A global pharmaceutical R&D executive credited with 14 drug approvals, he previously held senior roles at Nektar Therapeutics, Endo Health Solutions, Forest Laboratories, and SmithKline Beecham, and holds an MD from the University of London and an MBA from Wharton.
Contact· self-published, not guessed
Invests in
Biotech
Board director at Alveus Therapeutics
Intro paths
→
In turn, Ivan can intro founders to Alveus Therapeutics's investors below.
Alveus Therapeutics's investors · 9
Agent CapitalWaltham · since 2025Andera PartnersParis · since 2025Avego BioScience CapitalAlpharetta · since 2025Global BioAccess FundNew York · $10M checks · since 2025Jeito CapitalParis · since 2025Kurma PartnersParis · $162K – $10.8M checks · since 2026New Rhein Healthcare Investors, LLCPhiladelphia · since 2025Omega FundsBoston · since 2026Seroba Life SciencesDublin · $540K – $7.6M checks · since 2025
Board director at Neuraptive
Intro paths
→
In turn, Ivan can intro founders to Neuraptive's investors below.
Neuraptive's investors · 2
Experience
- Alveus Therapeutics IncChief Medical Officer (Interim)current2026 — presentCopenhagen, Philadelphia
- Alveus Therapeutics IncBoard Membercurrent2024 — presentCopenhagen, Philadelphia
- Corsair PharmaChairman of the Board of Directorscurrent2023 — present
- Theranica Bio-Electronics Ltd.Director Board of Directorscurrent2022 — present
- Butterfly MedicalDirector Board of Directorscurrent2020 — present
- New Rhein Healthcare InvestorsManaging Partner and Chief Medical Officercurrent2018 — presentPhiladelphia, London, Brussels
- Neuraptive TherapeuticsDirector Board of Directorscurrent2018 — present
- Travecta TherapeuticsDirector Board of Directors2021 — 2022
- Neurotrope Inc.Director Board of Directors2018 — 2020
- Realm Therapeutics, Inc.Director Board of Directors2016 — 2019
- CoriumDirector Board of Directors2014 — 2018
- Nektar TherapeuticsHead of Development & Chief Medical Officer2014 — 2017San Francisco Bay Area
- Endo PharmaceuticalsChief Scientific Officer2008 — 2014Malvern, Pennsylvania, United States
- Forest Laboratories (now Allergan)President R&D2003 — 2008New York, New York, United States
Skills & more
Clinical Trials25Lifesciences16Commercialization12R&D12Clinical Development11Biotechnology9Drug Development5Cross-functional Team Leadership4Clinical Research2Drug Discovery4Drug Delivery2Biopharmaceuticals3
+12 more
OncologyRegulatory AffairsTechnology TransferSopScienceInfectious DiseasesLife SciencesFDALeadershipStrategyPharmaceutical IndustryCROFrom Ivan's professional profile.
Deals · 1
NeuraptiveBoard seat
via New Rhein Healthcare Investors, LLC · filed Oct 2022 · $38.1M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Alveus TherapeuticsAlveus Therapeutics Inc.Butterfly Medical Ltd.Corium International Inc.Corsair PharmaNeurotrope Inc.Realm TherapeuticsTheranica
Sources: SEC Form D filings · the firm's website.
Colleagues at New Rhein Healthcare Investors, LLC
Akhil Akula
Vice President at New Rhein Healthcare Investors, LLC
Amy Bevacqua
Vice President at New Rhein Healthcare Investors, LLC
Bill Engels
Chief Finance Officer at New Rhein Healthcare Investors, LLC
Chris Ferris
Head of Investor Relations at New Rhein Healthcare Investors, LLC
Clarisa Gonsalves
Executive Administrative Assistant at New Rhein Healthcare Investors, LLC
Greg Parekh
Founder and Managing Partner at New Rhein Healthcare Investors, LLC
Jonathan Soll
Associate at New Rhein Healthcare Investors, LLC
Lauren Exposito
Investor Relations Associate at New Rhein Healthcare Investors, LLC
Frequently asked questions
- Who is Ivan Gergel?
- Ivan Gergel, MD, MBA, has been Managing Partner and Chief Medical Officer at New Rhein since 2017. A global pharmaceutical R&D executive credited with 14 drug approvals, he previously held senior roles at Nektar Therapeutics, Endo Health Solutions, Forest Laboratories, and SmithKline Beecham, and holds an MD from the University of London and an MBA from Wharton.
- Where does Ivan Gergel work?
- Ivan Gergel is Managing Partner at New Rhein Healthcare Investors, LLC and Board director at Alveus Therapeutics and Board director at Neuraptive.
- What does Ivan Gergel invest in?
- Ivan Gergel invests in Biotech.
- What check size does Ivan Gergel write?
- Ivan Gergel typically writes checks of $100K – $5M.
- What boards does Ivan Gergel sit on?
- Ivan Gergel holds tracked board seats at Alveus Therapeutics, Alveus Therapeutics Inc., Butterfly Medical Ltd., Corium International Inc., Corsair Pharma, Neuraptive, Neurotrope Inc., Realm Therapeutics, Theranica.
- Where did Ivan Gergel go to school?
- Ivan Gergel studied at The Wharton School (Master of Business Administration - MBA, Business Administration and Management); University of London (Doctor of Medicine - MD); Royal College of Psychiatrists (MRCPsych, Psychiatry).
Same school
Also attended The Wharton School1,557
Fred WilsonCo-founder & Partner at Union Square VenturesSarah GuoFounder & General Partner of ConvictionJosh KopelmanFounder and Partner at First Round CapitalAydin SenkutFounder & Managing Partner at FelicisKunal BahlCo-founder of Snapdeal; co-founder of Titan CapitalJack AbrahamFounder, CEO & Managing Partner of Atomic
+ 1,551 more
Also attended University of London95
Sandra SchwarzerInvestor at Index VenturesKarim GillaniGeneral Partner at Luge CapitalRoxanneCompliance Officer at Hummingbird VenturesRakesh MurriaCOO at Nauta CapitalJos WhiteGeneral Partner at Notion CapitalTeo Qi ShanInvestor Relations Associate at Jungle Ventures
+ 89 more
